State-of-the-art prospective quality-control systems entail the use of medically relevant, analyte-specific quality control limits. With analyte-specific limits broader than those generally used in the clinical laboratory, there will be fewer false rejections, fewer unnecessary reanalyses, and shorter delays in run reporting. If the analyte-specific limits are narrower than those used in the laboratory, more errors will be detected, but the user is at risk of identifying errors over which s/he and the manufacturer have little control. The use of various patient data quality-control algorithms is described. Conservatism is stressed in adopting manufacturers' guidelines for surrogate, nondestructive quality-control testing. A simple, optimized approach is suggested for the systematic retrospective review of proficiency data. Finally, an approach is presented for converting from older, previously accepted quality control procedures to more efficient analyte-specific quality control.
Today's clinical laboratory is rapidly transforming into an efficient and highly automated business, driven by many factors including the ever-decreasing reimbursement for laboratory tests, the development of miniaturized instrumentation for point-of-care applications, the consolidation of diverse analytical functions into single workstations operated under minimal supervision, networked laboratory and medical information systems, the sometimes blind acceptance of administrators for staff reductions, the existence of several highly efficient and competitive national reference laboratories, and the formation of large, extremely competitive, integrated healthcare delivery systems (commonly known as health systems) consisting of hospitals and primary and specialty care clinics. The highly competitive healthcare business has resulted in the merging, downsizing, and elimination of laboratories.
This laboratory metamorphosis has been expensive in terms of the dislocated and (or) unemployed technologist and laboratory scientist. The transformation tends to reduce the quality of services of both the clinical laboratory and the clinical laboratory industry. Table 1 shows the how some of the factors that enabled the transformation can potentially compromise laboratory quality. The nationwide drive to reduce costs has resulted in largescale replacement of medical technologists by less-trained medical laboratory technicians, increasing workloads, a higher reliance on general-purpose float and temporary personnel, and a reduction of supporting technical staff with the resulting deemphasis of training. The widespread trend of integrating the high-volume chemistry, hematology, and coagulation laboratory into a core laboratory can compromise quality as the pool of highly skilled technologists is reduced. Even the pathologist's role in the clinical laboratory continues to diminish given that anatomic pathology, the pathologist's primary responsibility, requires more attention as it increases in complexity while its reimbursement remains constant or decreases.
In these highly competitive times, the laboratory is more dependent on the laboratory industry than ever before. The laboratory not only needs well-designed, efficient instruments but also requires the manufacturer to continually improve those assays already in use and to provide robust, transferable reference intervals. Unfortunately, the manufacturer has been experiencing the changes associated with downsizing and mergers longer than the clinical laboratory and also may be delivering less than optimal assistance to its clinical customer (see Table 1 ). To complicate issues further, the perceived need to reduce costs has increased the power of various purchasing groups, which in turn has diminished the strength of the relationship between the clinical laboratory purchaser and the clinical laboratory manufacturer. Decisions to acquire instrumentation are thus based less on total quality and more on costs or even the procure-ment of additional instrumentation for other laboratory disciplines. Table 2 lists the clinical laboratory's determinants of high-quality testing. When well-trained and motivated technologists use high-quality assays according to standard operating procedures, the end result is usually highly accurate and precise testing. Because unacceptable results are sometimes produced even by the best systems, procedures must be devised to detect and correct the error situation and amend any erroneous patient results. This article deals with quality control and the detection and reduction of analytical error. I remind the reader that most laboratory mistakes occur not during the analytical phase but before or after testing. For example, Ross and Boone [1] reviewed 363 incidents that occurred in a tertiary-care hospital in 1987. In the 337 medical records investigated, preanalytical (missed or incorrectly interpreted laboratory orders, improper patient preparation, incorrect patient identification, wrong specimen container, and mislabeled or mishandled specimens) and postanalytical (delayed, unavailable, or incomplete results) mistakes accounted for 46% and 47% of the total incidents, respectively. Nonlaboratory personnel were responsible for 29% of the mistakes. Most of these errors were interdepartmental.
Quality control may be defined as the control of the testing process to ensure that test results meet their quality requirements [2, 3] . Quality control may be practiced prospectively and provide information about the acceptability of the most recent analytical run(s) or may be practiced retrospectively and provide information about past performance. Prospective quality control can involve the statistical analysis of reference samples, the review of patient data, and even instrument-based electronic checks. Retrospective quality control includes external quality assessment or proficiency testing, the use of summary quality-control data provided by a regional or manufacturer-supplied quality-control program, calibration checking of unlike analyzers, and even the follow-up of clinician inquiries.
Optimization of Reference Sample Quality Control
The practice of quality control evolved with the growing use of the multitest analyzer in the early 1970s. Laboratorians gradually realized that the application of Ϯ2s qualitycontrol limits to multitest analyzer quality-control data resulted in many falsely out-of-control events. When the specimens in the out-of-control run were reanalyzed, the analyst often discovered minimal differences between the original and repeat determinations. As early as 1974, Haven [4] expanded the allowable deviations of qualitycontrol results by defining a run as out of control if either a single control observation exceeded the Ϯ3s limits (a violation of the 1 3s control rule) or two observations exceeded the Ϯ2s limits (a violation of the 2 2s control rule). This approach was rationalized by Westgard's investigations into the efficiency and appropriateness of various laboratory qualitycontrol rules. In two seminal papers [5, 6] , he introduced a nomenclature for quality-control rules and procedures and used computer simulations to calculate two probabilities of detecting error: the probability of false rejection (rejection when there was no added analytical error) (P fr ) and the probability of error detection (detecting added analytical error) (P ed ). Plots of these probabilities vs the size of the analytical error, referred to as power functions, could be used to compare the error detection capabilities of various control rules and thus to propose optimal quality-control rules. Westgard showed that quality-control procedures should usually consist of two control rules, one sensitive to systematic error (shifts and trends) and the other sensitive to random error (increased imprecision). In a subsequent paper he described a quality-control procedure [7] consisting of a rule that screened for observations outside the Ϯ2SD control limits (the 1 2s control rule) and two rules that detected the occurrence of random error (the 1 3s control rule and the R 4s control rule) and three rules that detected systematic error (the 2 2s , 4 1s , and 10 x rules). This multirule combination, now referred to as the Westgard multirule control procedure, is available on virtually all laboratory information systems (LIS) and microcomputer-based chemistry analyzers. 1 Westgard and others soon realized that quality control should be specified by instrument or even by analyte. The 1 Nonstandard abbreviations: LIS, laboratory information system(s); MAE, medically allowable error; SDI, standard deviation index. Table 2 . Laboratory determinants of high-quality testing.
Well-trained, motivated technologists High-quality assays from laboratory industry Standard operating procedures Adequate quality control External quality assessment Intense spirit of quality improvement application of the six-rule multirule control procedure to highly precise analyses tended to detect small, sometimes insignificant analytical error. Westgard derived formulae to calculate the maximum analytical error that could be tolerated in a measurement process. Assuming an analyte with a maximum medically allowable error (MAE), an analytical process with an imprecision of s, and a maximum error prevalence of 5%, the largest systematic error that could be tolerated was: MAE/s Ϫ 1.66. The largest tolerable random error was (MAE/s)/2. Westgard used these maximum systematic and random errors and the power function diagrams to construct quality-control selection grids [8] . These grids permitted the selection of optimal quality-control rules for various amounts of tolerable error and error frequency. Westgard is now marketing a computer program [9] that allows the user to specify an analyte, its imprecision, and the MAE (usually the proficiency test limits as specified by the Clinical Laboratory Improvement Amendments of 1988). The program then proposes optimal quality-control procedures for that analyte.
The laboratorian is more motivated to use the optimized quality-control procedure if it reduces the frequency of quality control. Koch et al. [10] showed that the application of optimized analyte-specific quality-control practices reduced the frequency of falsely rejected runs, reduced quality-control expenses, and increased the efficiency of their high-volume chemistry analyzer, the Hitachi 737. Koch et al. replaced a quality-control procedure of the 1 3s , 2 2s , and the R 3.6s rules applied to 2 controls run for every 18 patients. This new control procedure consisted of the 1 3.5s rule for sodium, potassium, glucose, and blood urea nitrogen; the 1 2.5s rule for albumin, chloride, and CO 2 ; and the 1 2.5s rule for calcium, which was run in duplicate and averaged. Considerable reprograming of the LIS quality-control program and retraining of the analysts were needed for their analyte-specific qualitycontrol procedures to succeed.
The laboratorian is far less motivated to use the optimized quality-control procedure if it increases the frequency of quality-control testing or detects more occurrences of analytical error. Such optimized quality-control systems detect problems with which the manufacturer may not be able to help, thus causing more difficulty in convincing administrators and technologists of the added value of more sensitive procedures. It may be more effective to modify or even replace the analytical procedure for one more stable and requiring less sensitive quality control.
Quality Control Using Patient Results
In most clinical laboratories, reference sample qualitycontrol analysis is the primary indicator that an analytical process is achieving its quality requirements. Patient results are used to supplement reference sample quality control in the following circumstances: when the control product is very expensive or rapidly outdates; when the control product does not adequately simulate actual patient specimens; far more patient samples are analyzed than control specimens (e.g., in high-volume reference laboratories); for investigating abnormally occurring distributions of the patient results; and for checking preanalytical factors such as glycolysis.
Patient data can be evaluated on an individual basis or grouped to provide meaningful information about the analytical run. Markedly abnormal values, those defined as critical or panic, are followed with reanalysis, checking of previous values, or with expedited reporting to the clinician [11, 12] . Arithmetic checks may be done within a group of analytes, e.g., anion gap, to determine the acceptability of the constituent measurements or between a calculated parameter and the one actually measured (e.g., calculated bicarbonate from a blood gas measurement and the total serum CO 2 ). If a patient's previous results are available during the testing of the current specimen, the LIS can calculate the difference (⌬) between the current and previous measurements and indicate a significantly large ⌬. Houwen and Duffin [13] have proposed a unorthodox approach to the calculation of ⌬ that results in only one ⌬ for a set of current and previous test values:
where RL is the lower test result and RH is the higher test result.
In the typical calculation of ⌬, the magnitude of the ⌬ is greatly affected by the direction of the change. By the calculation of Houwen and Duffin, the ⌬ is the same whether the current value increases or decreases. I believe it is easier to apply than the more prevalent calculation.
Delta check violations should be investigated before reporting the current value. Such prospective investigations will prevent the reporting of erroneous results associated with the current determination. Although more efficient, investigations that occur after result reporting will lead to aberrant data reviewed by the clinical staff. If no errors are detected, the large ⌬ is usually attributed to either an analytical error in the first determination, mixup of the first specimen, or greater than expected intraindividual variation. Because of improved instrument reliability and the increasing use of bar-code identification of specimens, the prevalence of analytical errors and specimen mixups has been decreasing. Large ⌬ values will more often indicate a real change in a patient's test values rather than an error [14] . For this reason, ⌬ check limits should be considered for review on a per analyte basis whenever a technologist suggests that the ⌬ check limits are too narrow and are resulting in too frequent investigations.
Only a minority of laboratorians, usually hematologists, advocate the use of patient data over reference sample results to determine run acceptability. Most microcomputer-driven hematology analyzers are programed to average consecutive patient erythrocyte indices with a unique smoothing algorithm, named after Brian Bull who first described its use for quality control. As patient erythrocyte indices are symmetrically distributed and usually exhibit few extreme outlying values, the averages of as little as 20 observations are quite stable. Changes in serial average erythrocyte indices thus can indicate errors in the component measurements hemoglobin, erythrocyte count, and mean corpuscular volume. Simulations of Bull's averaging technique indicate that a minimum of 40 to 60 specimens must be analyzed daily for the method to have any error detection capabilities [15, 16] . As such, the averaging technique is not useful at start-up or after maintenance nor is it useful with instruments requiring frequent calibration. Smith and Kroft [17] have provided more general simulations of similar averaging techniques.
Although the averages of patient clinical chemistry data were originally described for quality control over 30 years ago [18] , a series of investigators found that the technique lacked the error-detection capabilities of reference sample quality control. The error-detection capabilities of patient averages depend on multiple factors [19] with the most important being the number of patient results averaged (N p ) and the ratio of the standard deviation of the patient population (s p ) to the standard deviation of the analytical method (s a ). Other important factors included the limits for evaluating the mean (control limits), the limits for determining which patient data are averaged (truncation limits), and the magnitude of the population lying outside the truncation limits. Douville et al. [20] have provided a formula for determining the number of patient results that must be averaged to provide the error-detection capabilities of N c controls.
Douville et al. recommended that the number of patient samples to be averaged should reflect at least two control specimens:
Westgard has recently studied distributions of reference laboratory data and fairly complex computer programs to calculate the number of patient data that must be averaged to provide meaningful information about run acceptability [21] . [22] and endocrine test analyzers [20] , only a few laboratories, usually large-volume reference laboratories, use patient averages for either prospective or retrospective quality control [23] . The many reasons for this low usage rate include the lack of sophisticated computer programs to smooth the patient data and then present meaningful graphic summaries of the both the patient and control data; limited experience in interpreting these summaries; and the fact that the patient mean can indicate changes in mix of patients rather than analytical error. Fig. 1 shows the daily means of patient potassium, sodium, calcium, and glucose for ϳ45 days in the summer of 1996 at Hotel Dieu, a tertiary care hospital in Quebec City, Canada. The day of the week is indicated on the abscissa. Also shown is the number of patients averaged to obtain the daily patient mean.
On Saturdays and Sundays ϳ50 to 100 fewer specimens are analyzed, and on these days the mean patient calcium, potassium, and sodium values drop but glucose values increase. Healthier patients tend to be discharged on weekends. Proportionately more sick patients are hospitalized on weekends and cause these changes. In the future, as more moderately ill patients are treated on an outpatient basis rather than being admitted to the hospital, the increased proportion of sick inpatients will cause even greater swings on weekends and holidays. The reader should be reminded that results outside of reference limits (the truncation limits) are not being averaged, and these temporal variations are occurring in the truncated data. Patient data averages are also sensitive to outlying groups of patient results, e.g., those from nephrology and dialysis clinics. As such, it would be advantageous to identify such results and exclude them from averaging.
The greatest usefulness of patient data averages for prospective quality control will be in reference and outpatient laboratories that receive large proportions of specimens with few abnormal tests. If multiple analyzers are operated simultaneously, it would be useful to randomize the specimens among the analyzers, thus decreasing the probability of a single instrument analyzing large groups of specimens from a single source such as a dialysis center. Douville et al. provided guidelines for exponential smoothing of the patient data [20] , thus simplifying the calculation of patient averages for any desired run length. In an interesting use of patient averages, Miller [24] periodically calculates patient averages to determine the need for recalibration of multiple chemistry analyzers at the Medical College of Virginia.
Point-of-Care Quality-Control Practices
Glucose reflectance meters represent one of the first of point-of-care devices to be introduced into hospitals. Quality-control programs for point-of-care testing can thus be patterned after those for whole-blood glucose testing. Kiechle and I [25] provided a model for wholeblood glucose testing at William Beaumont Hospital in Royal Oak, MI. The program includes: (a) two levels of quality control each shift the device is used; (b) one fasting laboratory correlation per operator per day within ϩ15% of the laboratory value; (c) meter results Ͻ500 mg/L (Ͻ2.8 mmol/L) or Ͼ4000 mg/L (Ͼ22.2 mmol/L) verified by laboratory glucose determination; (d) proficiency testing once per trimester; (e) all personnel trained to receive initial authorization; and (f) annual skills validation or reauthorization. Stabilized blood products may be used for additional laboratory-originated proficiency testing. The cost of whole-blood glucose testing at William Beaumont for 4500 reported patient meter glucoses was $9.07 per patient glucose, compared with $1.22 per central laboratory glucose. Of the $9.07, $0.59 is expended for quality-control testing, and another $1.82 is used by the laboratory for training, oversight, and quality assurance.
Because many point-of-care analyzers are more precise and accurate than whole-blood glucose meters, their manufacturers recommend extremely limited reference sample quality-control testing or, alternatively, daily electronic quality control. I recommend that the laboratory community and regulators be conservative in approving such limited reference sample quality control. Most pointof-care analyzers are relatively new, and their evaluations have been short-term and performed under ideal conditions. The error-detection capabilities of point-of-care analyzers are not well characterized. For each point-ofcare analyzer, the manufacturer must compile a database of instrument malfunctions, error indicators, and the results of running the electronic control and reference specimens. Eventually, the manufacturer should be able to gather enough data to convince the regulator (and laboratorian) of the soundness of the limited reference sample approach.
External Quality Assessment and Quality Control
Because of the great emphasis on proficiency testing in CLIA 88 [26, 27] , laboratorians have gone to great lengths to assure successful proficiency testing. Although more effort is directed at reducing preanalytical and analytical variation and postanalytical reporting errors, and thus decreasing the probability of unsuccessful performance, little is expended in interpreting proficiency results to determine the existence of potentially correctable error conditions. This lack of effort is the result of the historical usage of only two or three unknowns to assess analytical accuracy. The review of so few results provides relatively little information about the acceptability of an analytical run and about the presence of substantial random or systematic error. Under CLIA 88, far more information about systematic and random error is provided, as Health Care Financing Administration (HCFA)-regulated analytes require a minimum of five unknown specimens to be analyzed. Cembrowski et al. [28] have proposed a multirule system to evaluate the HCFA-mandated proficiency test results: (a) a screening rule; (b) a rule for the detection of systematic error; and (c) two rules for the detection of random error. The rules are use multiples of the standard deviation index (SDI) which is calculated from: SDI ϭ (laboratory value Ϫ group mean)/group standard deviation. The rules follow:
If two or more observations are outside the same ϩ1 SDI limit or Ϫ1 SDI limit, the screening rule is violated and the data are then tested with rules specific for systematic and random error. This rule is usually violated in the presence of shifts exceeding 1.0 SDI and increases in random error Ͼ200%.
mean rule: x 1.5sdi If the average of the five observations exceeds 1.5 SDI or is less than Ϫ1.5 SDI, substantial systematic error is present. The magnitude of the systematic error is equal to the magnitude of the average.
3sdi rule
If one or more observations is outside either the ϩ3SDI or the Ϫ3SDI limits, a high probability of random error exists.
r 4sdi rule
If the range or the difference between the largest and the smallest proficiency testing result exceeds 4SDI, a high probability of random error exists.
Because of the high specificity of the follow-up rules, their violation should be followed by review of the laboratory records including the internal quality-control results. Mixups of proficiency specimens or of proficiency and clinical specimens should be excluded. Whenever possible, an aliquot of the survey specimen should be saved and reassayed for the analytes that yield erroneous results. Results that still deviate significantly after retesting indicate a long-term bias. If the deviations are variable in magnitude and direction, there may be a problem with random error. In the event that repeat analysis yields satisfactory results, the error probably represented a random error or transient bias encountered during the testing period.
The multirule system for inspecting proficiency testing data is simple and easy to teach. Its use results in a uniform style of proficiency test evaluation by supervisor, doctoral, or pathologist director. We have been using this multirule approach in several laboratories for the last 4 years [29] and have formally evaluated its application to 16 months of immunoassay testing in two laboratories [30] . Significant sources of both random and systematic error have been discovered and corrected by this technique. Many proficiency test programs do not provide SDI summaries of the participant's data. Lack of SDI summaries indicates that the proficiency test provider is marketing a suboptimal product.
Current Quality ControlOClimbing the Tower of Babel
Many quality control procedures have been proposed for the clinical laboratory; more are in the research and development pipeline. Surprisingly, even in 1997, the 1 2s control rule appears to be the most common single quality-control rule used for analytical run rejection [31] . More than 20 years have passed since Haven published his multirule approach and Westgard started to develop the tools for designing more efficient quality-control practices. In the 1994 survey of 505 College of American Pathologists Q-Probe subscribers, Tetrault and Steindel [31] documented great interlaboratory variation in the use of quality-control rules. About 25% of the clinical chemistry laboratories used the complete six-rule Westgard multirule; 20% used the Haven multirule, and another 15% used a subset of the Westgard multirule. In hematology, 9%, 12%, and 5% used the complete Westgard, Haven multirule, and Westgard subset, respectively. In the survey, 30% of the respondents claimed to use analyte-specific medical decision limits for quality control. Tetrault and Steindel found, however, that the medical decision limits used by the participants for quality control were often equal to the usual statistical quality-control limits. The implication of this finding is that many laboratorians do not understand the concept of analyte-specific quality control.
Twenty years after more-efficient quality-control practices were introduced to the laboratory, their application is still uneven. It is simple to ascribe the lack of uniformity to numeric agnosia. The most important reason, however, for such heterogeneous quality-control practices is that many of the current quality-control procedures were developed locally more than a decade ago and have not changed significantly since their original implementation. Laboratorians are reluctant to change systems if they are perceived to be working satisfactorily. A recent survey of quality-control practices in over 370 US hospital laboratories [32] indicates that 50% of the respondents believe that their staff who make daily decisions about run reliability and accuracy have at least an average understanding of statistical process control rules; another 36% believe that their staff have an above-average understanding; another 4% put their staff in the "expert" category. Such high levels of understanding imply a high satisfac-tion with their quality-control knowledge and indirectly with their quality-control systems.
Change to more-efficient, analyte-specific quality-control procedures will thus not arise de novo in a laboratory. There must a precipitating event including the acquisition of a multichannel analyzer or laboratory information system with the facility for analyte-specific quality control. Second, there must be a change agent in the laboratory who believes that the usage of newer quality-control practices will decrease the probability of false rejections. The change agent or her/his delegate must be skilled in laboratory quality control and either manually calculate MAE and then use Westgard's quality-control selection grids [8] or else use Westgard's quality-control microcomputer program [9] or a related manual [33] . The qualitycontrol procedure must be set up in the analyzer software or LIS and tested. Finally, the quality-control procedure must be written, and all of the laboratory staff must be trained. Unfortunately, such conversions are major undertakings in today's down-sized laboratory.
